Ipsen SA

New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS

14 Jan 2026 01:00:00 By Nasdaq GlobeNewswire

U.S. FDA grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in first line unfit Acute Myeloid Leukemia

13 Jan 2026 12:19:49 By Nasdaq GlobeNewswire

Ipsen - December 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Jan 2026 12:30:00 By Nasdaq GlobeNewswire

Ipsen – Half year statement – 2025 12 31

06 Jan 2026 12:00:00 By Nasdaq GlobeNewswire

Ipsen expands early development pipeline with Simcere Zaiming’s innovative antibody drug conjugate

22 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP)

19 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline

15 Dec 2025 11:30:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025

09 Dec 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen - November 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

08 Dec 2025 12:30:00 By Nasdaq GlobeNewswire

Ipsen provides update on legacy of Henri Beaufour

05 Dec 2025 00:58:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 48 - 2025

02 Dec 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen mourns the passing of Henri Beaufour, a founding family Board member

01 Dec 2025 01:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 47 - 2025

25 Nov 2025 12:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 46 - 2025

19 Nov 2025 12:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2025

12 Nov 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen - October 2025 - Monthly information relative to the total number of voting rights and shares composing the share capital

07 Nov 2025 12:00:00 By Nasdaq GlobeNewswire

Ipsen to present two late-breaking sessions at AASLD on new PBC data supporting IQIRVO®’s long-term efficacy, safety and mechanistic insights in fatigue

07 Nov 2025 08:42:43 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2025

06 Nov 2025 12:00:00 By Nasdaq GlobeNewswire

IPSEN - Buy-back programme - Art 5 of MAR - Week 43 - 2025

28 Oct 2025 13:00:00 By Nasdaq GlobeNewswire

Ipsen delivers strong sales in the first nine months of 2025 and further upgrades its full-year guidance

22 Oct 2025 01:05:00 By Nasdaq GlobeNewswire